SUGAR LAND, TX--(Marketwire -06/18/12)- Reported by Annette Kreuger for Industrial Information Resources Sugar Land, Texas) -- Once construction has wrapped up and the validation process for a new pharmaceutical or biotech (pharma-bio) plant is complete, it is time to begin production. Not only does an operational plant manufacture drug products that improve the public's physical health, but it also sets off a ripple effect that is beneficial to the financial well being of the host community, county and state.

In the past 12-month period (6/2011-6/2012), 83 new Pharmaceutical & Biotech Industry plants began operations in North America. Industrial Info is tracking 185 additional new-build (or lease and equip) projects in various stages of planning, engineering or construction.

For details, view the entire article by subscribing to Industrial Info's Premium Industry News at http://www.industrialinfo.com/showAbstract.jsp?newsitemID=224180&refer=mw, or browse other breaking industrial news stories at http://www.industrialinfo.com.

Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, and eight offices outside of North America, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. To contact an office in your area, visit the http://www.industrialinfo.com "Contact Us" page.

See the original post here:
Anatomy of a Drug Manufacturing Plant (Last in a Three-Part Series Examining the Financial Impact of New Plant ...